Robert Widdop

8PUBLICATIONS
62CO-AUTHORS
Molecular targetsCardiology (incl. cardiovascular diseases)Biologically active moleculesReproductionBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 01, 2025
The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis.

Simon G Royce, Cem Erdem, WeiYi Mao

|Jun 09, 2025
Novel Mouse Model of Coronary Atherosclerosis With Myocardial Infarction: Insights Into Human CAD.

Hong Chen, Qing Wan, Jianfeng Yang

|Jul 01, 2024
Angiotensin-(1-5) is a Potent Endogenous Angiotensin AT 2 -Receptor Agonist.

Igor M Souza-Silva, A Augusto Peluso, Khalid Elsaafien

|Nov 26, 2022
The Novel AT2 Receptor Agonist β-Pro7-AngIII Exerts Cardiac and Renal Anti-Fibrotic and Anti-Inflammatory Effects in High Salt-Fed Mice.

Yan Wang, Jonathan Yodgee, Mark Del Borgo

|Apr 04, 2022
Relaxin Attenuates Organ Fibrosis via an Angiotensin Type 2 Receptor Mechanism in Aged Hypertensive Female Rats.

Giannie Barsha, Sarah L Walton, Edmund Kwok

|Jul 22, 2020
Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity.

Eirinaios I Vrettos, Ibai E Valverde, Alba Mascarin

Pageof 2

Frequent Collaborators

3 joint publications

Chrishan S Samuel

2 joint publications

Mark Del Borgo

2 joint publications

Ivan Maslov

1 joint publications

U Muscha Steckelings